This subclassification can be performed by panel of monoclonal antibodies against the following antigens: CD10, MUM1, BCL-6 and consequently, patients are clustered into two groups according to their immunophenotypic profile in order to assess the pattern of differentiation.
The main purpose of this study was to identify the clinical features and outcome of extranodal DLBCL among Egyptian patients, as well as their classification according to Hans' system.
Patients and methods
We studied retrospectively all patients diagnosed as extranodal DLBCL presented to the Medical Oncology Clinic, National Cancer Institute, Cairo University during the period from January 2008 to December 2010. Fiftyseven patients had available paraffin blocks and clinical data and consequently, were included in the study. Clinical data were retrieved from patients' files including; age, sex, site, performance status, laboratory investigations (CBC, liver and kidney functions, bone marrow aspirate and biopsy), radiological data (CT neck, chest, abdomen and pelvis), upper and lower Gastrointestinal Track endoscopy for GIT lymphoma, stage according to modified Ann Arbor criteria, initial chemotherapy, response, treatment of refractory/relapsed cases, date of relapse, date of last visit and state.
The paraffin blocks of cases were retrieved and Hx&E sections were prepared for histopathologic evaluation in correlation with the immunostained slides for revision of their immunophenotyping. Three sections were prepared from each paraffin block (4 microns thick) and immunostained using primary monoclonal antibodies against CD10 (clone 56C6, ready to use, DAKO), BCL-6 (clone PG-B6p, ready to use, DAKO), and MUM-1 (clone MRQ-8, ready to use, Cell Marque) using Bench Mark VentanaAutostainer (XT). Positive reaction was considered at cut-off point 30% of all markers. Cases were classified according to Hans Algorithm4 into; 1. Positive CD10 meant that it was of GC subtype and it was must for all cases having non-GC tumours to have negative CD10 immunostaining, 2. Cases that had negative CD10 with negative BCL-6 were all of non-GC group, while cases with negative CD10 and positive BCL-6 were further evaluated for MUM-1; if positive MUM-1 then they were GC subtype but if negative, they were non-GC.
Disease-free survival was calculated from the date of complete remission till the date of relapse/death or last follow-up for non-relapsed patients. Overall survival was calculated from the date of diagnosis to the date of death/last follow-up.
Data were analysed using SPSS (version 16). Numerical data were expressed as means with standard deviation and range. Qualitative data were expressed as frequency and percentage. Survival analysis was done using the Kaplan-Meier method. Comparison between survival curves was done using the Log-rank test. P value < 0.05 was considered significant.
Result
The patients included 25 men (44%) and 32 women (56%) with a median age of 48 years (range 21-78 years). Fifty-two patients received CHOP as the firstline chemotherapy, at that time, patients could not receive Rituximab, which is standard for a B-cell NHL, as Rituximab was not avialable for our patients due to lack of resources and 6 of them received Involved Field Radiation Therapy (IFRTH) after the end of 4-6 cycles. Five cases received COP because of old age (> 60 years, 4 cases), poor performance status (2 cases) and/or associated cardiac disease (one case). Six patients received radiotherapy after finishing chemotherapy. Thirty-seven patients (64.9%) achieved CR while eighteen patients (31.6%) failed. No significant difference between GC and non-GC groups regarding frequency of CR (66.7% versus 64.3%; respectively, p = 0.247). On the contrary, stage had marked impact on the incidence of CR; as it occurred in 85.2% in patients with localised disease comparison to 53.3% in patients with advanced disease, with statistical significant difference (p = 0.008). Relapse occurred in seven patients (18.9%) out of all patients who achieved CR. It occurred either localised in the same primary site or disseminated in CNS, skin, liver and kidney.
The 3-year OS survival for the entire patients was 54.3%. The main causes of death were neutropenia, disease progression and liver cell failure. No difference was found between GC subtype and non-GC subtype regarding OS (figure 1), 53.3 versus 52.4% (p = 0.656). Advanced stage had worsened the OS by 40% in comparison to localised disease where OS was 66.7% (figure 2), but statistical significant difference could not be achieved (p = 0.19). OS for patients with low-risk IPI was significantly better than patients with intermediate or high IPI (p = 0.08).
Discussion
NHL is a heterogeneous neoplasm regarding presentation, response to therapy and outcome. The classification of NHL as primary nodal or extranodal is a controversial issue (6) . Patients with purely nodal or extranodal are easily classified. In some studies, only localised extranodal lymphomas had been defined as PE NHL (7). In other studies, classification of NHL is mainly based on the clinicopathologic features, but not taking into consideration the primary site of NHL (8) .
Currently, the prognosis for patients with DLBCL is estimated by using the clinical parameters of the IPI that reflects mixture of underlying biologic and genetic differences. Some studies tried to elucidate the underlying factors using molecular techniques using cDNA microarray dividing DLBCL into GC B-cell like, activated B-cell like (ABC) and type 3 gene expression profile (9) . The latter is heterogeneous and has a poor outcome similar to the ABC group, both lumped into non-GC group (10) . Because this technology is expensive and not generally available, a simpler, more widely available method to subclassify DLBCL into molecularly distinct and prognostically significant groups; GC and non-GC, using immunohistochemistry would have wide applicability. The most commonly used panel is CD10, BCL-6, and MUM1. However, the results are conflicting, some authors found no difference in the outcome between GC and non-GC groups (11, 12) while others obtained better survival for GC group (10, 13) .
In our study, 57 cases were included with primary tumour sites included; gastrointestinal (17 cases, 29.9%), liver (13 cases, 22.9%), upper aerodigestive (8 cases, 14.1%), bone (5 cases, 8.8%), lung and pleura (4 cases, 7%), kidney (2 cases, 3.5%), spleen (2 cases), soft tissue (2 cases), testis (1 case, 1.7%), ovary (1 case), breast (1 case) and parotid (1 case). We noticed high prevalence of liver being affected than Western as shown by Lopez-Guillermo (14) , who documented liver cases in only 2% of their patients. This could be due to the high prevalence of hepatitis B and C in our country predisposing to increase in liver NHL (15) . On the other hand, their CNS cases are about 2.5% comparable to none in our study.
In our study, 37 patients (64.9%) achieved complete remission (CR), which is lower than what was reported by Lal et al. (2008) 16 , which was 74.4%, but the difference could be attributed to that all their cases were stage I and II, while 54.6% of our cases were advanced stage (III and IV). No significant difference between GC and non-GC groups regarding frequency of CR (66.7 versus 64.3%, p = 0.247). On the contrary, stage had marked impact on the incidence of CR; as it occurred in 85.2% in patients with localised disease in comparison with 53.3% in patients with advanced disease, with statistical significant difference (p = 0.008). This was coincident with what was found by Lopez-Guillermo (14) who reported high CR among patients of early stage but not correlated with typing into GC or non-GC.
The 3-year OS survival for the entire patients was 54.3% with no difference was found between GC subtype and non-GC subtype regarding OS, 53.3 versus 52.4% (p = 0.656). Advanced stage and intermediate/ high-risk IPI were unfavourable prognostic factor of OS. Same findings were reported in other studies (14) where 5-year OS was 52% with unfavourable predictors were poor IPI and advanced stage.
In conclusion, extranodal DLBCL showed a high prevalence of liver in Egyptian population, probably due to widespread hepatitis B and C virus in Egypt. Stage and IPI are the main prognostic factors for patients' outcome. Classification of DLBCL into GC and non-GC subtypes remains a controversial issue with no consensus regarding its relation to prognosis, requiring more extensive studies on larger population. 
